The Role of Interruptions in polyQ in the Pathology of SCA1

English version České info

At least nine dominant neurodegenerative diseases are caused by expansion of CAG repeats in coding regions of specific genes that result in abnormal elongation of polyglutamine (polyQ) tracts in the corresponding gene products. When above a threshold that is specific for each disease the expanded polyQ repeats promote protein aggregation, misfolding and neuronal cell death. The length of the polyQ tract inversely correlates with the age at disease onset. It has been observed that interruption of the CAG tract by silent (CAA) or missense (CAT) mutations may strongly modulate the effect of the expansion and delay the onset age. We have carried out an extensive study in which we have complemented DNA sequence determination with cellular and biophysical models. By sequencing cloned normal and expanded SCA1 alleles taken from our cohort of ataxia patients we have determined sequence variations not detected by allele sizing and observed for the first time that repeat instability can occur even in the presence of CAG interruptions. We show that histidine interrupted pathogenic alleles occur with relatively high frequency (11%) and that the age at onset inversely correlates linearly with the longer uninterrupted CAG stretch. This could be reproduced in a cellular model to support the hypothesis of a linear behaviour of polyQ. We clarified by in vitro studies the mechanism by which polyQ interruption slows down aggregation. Our study contributes to the understanding of the role of polyQ interruption in the SCA1 phenotype with regards to age at disease onset, prognosis and transmission.

Vyšlo v časopise: The Role of Interruptions in polyQ in the Pathology of SCA1. PLoS Genet 9(7): e32767. doi:10.1371/journal.pgen.1003648
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1003648

Souhrn

Zdroje

1. OrrHT, ZoghbiHY (2007) Trinucleotide repeat disorders. Annu Rev Neurosci 30: 575–621.

2. RossCA, PoirierMA (2004) Protein aggregation and neurodegenerative disease. Nat Med 10 Suppl: S10–17.

3. ScherzingerE, SittlerA, SchweigerK, HeiserV, LurzR, et al. (1999) Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci U S A 96: 4604–4609.

4. KazantsevA, PreisingerE, DranovskyA, GoldgaberD, HousmanD (1999) Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A 96: 11404–11409.

5. SchölsL, AmoiridisG, ButtnerT, PrzuntekH, EpplenJT, et al. (1997) Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 42: 924–932.

6. ZoghbiHY, OrrHT (2000) Glutamine repeats and neurodegeneration. Annu Rev Neurosci 23: 217–247.

7. DürrA (2010) Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol 9: 885–894.

8. PerutzMF (1996) Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr Opin Struct Biol 6: 848–858.

9. PerutzMF, FinchJT, BerrimanJ, LeskA (2002) Amyloid fibers are water-filled nanotubes. Proc Natl Acad Sci U S A 99: 5591–5595.

10. AltschulerEL, HudNV, MazrimasJA, RuppB (1997) Random coil conformation for extended polyglutamine stretches in aqueous soluble monomeric peptides. J Pept Res 50: 73–75.

11. BennettMJ, Huey-TubmanKE, HerrAB, WestAPJr, RossSA, et al. (2002) A linear lattice model for polyglutamine in CAG-expansion diseases. Proc Natl Acad Sci U S A 99: 11634–11639.

12. ChenS, WetzelR (2001) Solubilization and disaggregation of polyglutamine peptides. Protein Sci 10: 887–891.

13. KleinFA, PastoreA, MasinoL, Zeder-LutzG, NierengartenH, et al. (2007) Pathogenic and non-pathogenic polyglutamine tracts have similar structural properties: towards a length-dependent toxicity gradient. J Mol Biol 371: 235–244.

14. MasinoL, KellyG, LeonardK, TrottierY, PastoreA (2002) Solution structure of polyglutamine tracts in GST-polyglutamine fusion proteins. FEBS Lett 513: 267–272.

15. MorleyJF, BrignullHR, WeyersJJ, MorimotoRI (2002) The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A 99: 10417–10422.

16. SharmaD, ShinchukLM, InouyeH, WetzelR, KirschnerDA (2005) Polyglutamine homopolymers having 8–45 residues form slablike beta-crystallite assemblies. Proteins 61: 398–411.

17. SikorskiP, AtkinsE (2005) New model for crystalline polyglutamine assemblies and their connection with amyloid fibrils. Biomacromolecules 6: 425–432.

18. AlbàMM, Santibáñez-KorefMF, HancockJM (1999) Conservation of polyglutamine tract size between mice and humans depends on codon interruption. Mol Biol Evol 16: 1641–1644.

19. PearsonCE, EichlerEE, LorenzettiD, KramerSF, ZoghbiHY, et al. (1998) Interruptions in the triplet repeats of SCA1 and FRAXA reduce the propensity and complexity of slipped strand DNA (S-DNA) formation. Biochemistry 37: 2701–2708.

20. OrrHT, ChungMY, BanfiS, KwiatkowskiTJJr, ServadioA, et al. (1993) Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 4: 221–226.

21. ChongSS, McCallAE, CotaJ, SubramonySH, OrrHT, et al. (1995) Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet 10: 344–350.

22. SobczakK, KrzyzosiakWJ (2004) Patterns of CAG repeat interruptions in SCA1 and SCA2 genes in relation to repeat instability. Hum Mutat 24: 236–247.

23. ImbertG, SaudouF, YvertG, DevysD, TrottierY, et al. (1996) Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 14: 285–291.

24. PulstSM, NechiporukA, NechiporukT, GispertS, ChenXN, et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14: 269–276.

25. SanpeiK, TakanoH, IgarashiS, SatoT, OyakeM, et al. (1996) Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 14: 277–284.

26. GiuntiP, SabbadiniG, SweeneyMG, DavisMB, VenezianoL, et al. (1998) The role of the SCA2 trinucleotide repeat expansion in 89 autosomal dominant cerebellar ataxia families. Frequency, clinical and genetic correlates. Brain 121: 459–467.

27. QuanF, JanasJ, PopovichBW (1995) A novel CAG repeat configuration in the SCA1 gene: implications for the molecular diagnostics of spinocerebellar ataxia type 1. Hum Mol Genet 4: 2411–2413.

28. FrontaliM, NovellettoA, AnnesiG, JodiceC (1999) CAG repeat instability, cryptic sequence variation and pathogeneticity: evidence from different loci. Philos Trans R Soc Lond B Biol Sci 354: 1089–1094.

29. SenS, DashD, PashaS, BrahmachariSK (2003) Role of histidine interruption in mitigating the pathological effects of long polyglutamine stretches in SCA1: A molecular approach. Protein Sci 12: 953–962.

30. CalabresiV, GuidaS, ServadioA, JodiceC (2001) Phenotypic effects of expanded ataxin-1 polyglutamines with interruptions in vitro. Brain Res Bull 56: 337–342.

31. JayaramanM, KodaliR, WetzelR (2009) The impact of ataxin-1-like histidine insertions on polyglutamine aggregation. Protein Eng Des Sel 22: 469–478.

32. ChungMY, RanumLP, DuvickLA, ServadioA, ZoghbiHY, et al. (1993) Evidence for a mechanism predisposing to intergenerational CAG repeat instability in spinocerebellar ataxia type I. Nat Genet 5: 254–258.

33. RanumLP, ChungMY, BanfiS, BryerA, SchutLJ, et al. (1994) Molecular and clinical correlations in spinocerebellar ataxia type I: evidence for familial effects on the age at onset. Am J Hum Genet 55: 244–252.

34. JodiceC, MalaspinaP, PersichettiF, NovellettoA, SpadaroM, et al. (1994) Effect of trinucleotide repeat length and parental sex on phenotypic variation in spinocerebellar ataxia I. Am J Hum Genet 54: 959–965.

35. MatsuyamaZ, IzumiY, KameyamaM, KawakamiH, NakamuraS (1999) The effect of CAT trinucleotide interruptions on the age at onset of spinocerebellar ataxia type 1 (SCA1). J Med Genet 36: 546–548.

36. GaoR, ZhaoAH, DuY, HoWT, FuX, et al. (2012) PCR artifacts can explain the reported biallelic JAK2 mutations. Blood Cancer J 2: e56.

37. de ChiaraC, MenonRP, Dal PiazF, CalderL, PastoreA (2005) Polyglutamine is not all: the functional role of the AXH domain in the ataxin-1 protein. J Mol Biol 354: 883–893.

38. MenonRP, PastoreA (2006) Expansion of amino acid homo-sequences in proteins: insights into the role of amino acid homo-polymers and of the protein context in aggregation. Cell Mol Life Sci 63: 1677–1685.

39. TsaiCC, KaoHY, MitzutaniA, BanayoE, RajanH, et al. (2004) Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors. Proc Natl Acad Sci U S A 101: 4047–4052.

40. ParfittDA, MichaelGJ, VermeulenEG, ProdromouNV, WebbTR, et al. (2009) The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1. Hum Mol Genet 18: 1556–1565.

41. LamYC, BowmanAB, Jafar-NejadP, LimJ, RichmanR, et al. (2006) ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 127: 1335–1347.

42. MizutaniA, WangL, RajanH, VigPJ, AlaynickWA, et al. (2005) Boat, an AXH domain protein, suppresses the cytotoxicity of mutant ataxin-1. EMBO J 24: 3339–3351.

43. TsudaH, Jafar-NejadH, PatelAJ, SunY, ChenHK, et al. (2005) The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122: 633–644.

44. KlementIA, SkinnerPJ, KaytorMD, YiH, HerschSM, et al. (1998) Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95: 41–53.

45. EmamianES, KaytorMD, DuvickLA, ZuT, TouseySK, et al. (2003) Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38: 375–387.

46. WankerEE, ScherzingerE, HeiserV, SittlerA, EickhoffH, et al. (1999) Membrane filter assay for detection of amyloid-like polyglutamine-containing protein aggregates. Methods Enzymol 309: 375–386.

47. ScherzingerE, LurzR, TurmaineM, MangiariniL, HollenbachB, et al. (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90: 549–558.

48. BuloneD, MasinoL, ThomasDJ, San BiagioPL, PastoreA (2006) The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils. PLoS One 1: e111.

49. LeVineH3rd (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404–410.

50. NaikiH, HiguchiK, HosokawaM, TakedaT (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal Biochem 177: 244–249.

51. ZuhlkeC, HellenbroichY, SchaaffF, GehlkenU, WesselK, et al. (1997) CAG repeat analyses in frozen and formalin-fixed tissues following primer extension preamplification for evaluation of mitotic instability of expanded SCA1 alleles. Hum Genet 100: 339–344.

52. GiovannoneB, SabbadiniG, Di MaioL, CalabreseO, CastaldoI, et al. (1997) Analysis of (CAG)n size heterogeneity in somatic and sperm cell DNA from intermediate and expanded Huntington disease gene carriers. Hum Mutat 10: 458–464.

53. CannellaM, MaglioneV, MartinoT, RagonaG, FratiL, et al. (2009) DNA instability in replicating Huntington's disease lymphoblasts. BMC Med Genet 10: 11.

54. MøllersenL, RoweAD, LarsenE, RognesT, KlunglandA (2010) Continuous and periodic expansion of CAG repeats in Huntington's disease R6/1 mice. PLoS Genet 6: e1001242.

55. ChastainPD2nd, EichlerEE, KangS, NelsonDL, LeveneSD, et al. (1995) Anomalous rapid electrophoretic mobility of DNA containing triplet repeats associated with human disease genes. Biochemistry 34: 16125–16131.

56. Subramony SHaA, T. (1998) Spinocerebellar Ataxia Type 1. Ed: Pagon,R.A., Bird,T.D., Dolan,C.R. GeneReviewsTM [Internet]. Seatle: University of Washington. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1184.

57. YangY, JungDW, BaiDG, YooGS, ChoiJK (2001) Counterion-dye staining method for DNA in agarose gels using crystal violet and methyl orange. Electrophoresis 22: 855–859.

58. SkinnerPJ, KoshyBT, CummingsCJ, KlementIA, HelinK, et al. (1997) Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 389: 971–974.

59. de ChiaraC, MenonRP, StromM, GibsonTJ, PastoreA (2009) Phosphorylation of S776 and 14-3-3 binding modulate ataxin-1 interaction with splicing factors. PLoS One 4: e8372.